Tag Archives: IPO

Choose Your Own Adventure – The Private Biotech Crossroads

It is a known fact within the private company biopharma universe that the days of certainty for public exits, subsequent private financings, and even pharma licensing deals are over. IPOs have been out of favor for five years, venture firms are turning away from the sector, and fewer licensing deals are being cut. What is less understood about this uncertain environment is how it has forced management and their venture backers, to not only rethink Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Indices, IPOs, Approvals – YTD Update Aug 14th, 2012

Stock Ticker

We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed out a modest size IPO class, and delivered double digit novel FDA approvals. 1. Indices. The Nasdaq Biotech Index (NBI) is up 27% Year to Date (YTD) as of last Friday. It was up nearly 20% by the end of the 1st quarter, consolidated during the 2nd quarter, and has participated in the summer rally to tack on another 7%. Here Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

Index-Perfomance-June-2012-thumb

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M.  The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Indices, IPOs, and New Drug Approvals – Update April 3rd 2012

Index-March-20121

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Biofuels Digest Measures Bioenergy Business Outlook

biofuel-plant-btn

Biofuels Digest and BIO launched the 2012 Q1 Bioenergy Business Outlook Survey. In the last survey, Biofuels Digest reported that 79 percent of bioenergy executives are more optimistic both about their organization’s prospects for growth and industry growth, than 12 months prior. Bioenergy, biofuel and biotech executives are invited to participate in the survey. Overall, the survey painted a picture of an industry that is expecting to grow at nearly triple the growth rate of Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,